Catalent (CTLT) Misses Q1 EPS by 5c

Catalent, Inc. Reports First Quarter 2016 Results

Revenue increased 1% as reported and 11% in constant currency to $423.0 million from first quarter 2015; organic revenue growth of 9% Adjusted Net Income increased 54% to $20.7 million from first quarter 2015 Launched the new OptiForm® Solution Suite platform at the CPhI Worldwide Conference, designed to pair the optimal, most innovative drug delivery technologies to each developmental molecule with the commitment to provide candidate formulations Announced Dr. Donald E. Morel will be joining its Board of Directors On October 29, 2015,... More

Catalent, Inc. Appoints Donald E. Morel to its Board of Directors

SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that Dr. Donald E. Morel will be added to its Board of Directors, effective the next time the Board convenes, increasing the size of the Board to ten members.

Dr. Morel retired in June 2015 as Chairman of West Pharmaceutical Services, Inc. (West), a leading manufacturer of packaging components and delivery systems for injectable drugs and healthcare products, a position he had held... More